Kurzfassung

A Phase III, Open-Label, Randomised Study to
Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next
Generation, Oral Selective Estrogen Receptor Degrader) Versus
Standard Endocrine Therapy (Aromatase Inhibitor or
Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2-
Early Breast Cancer and an Intermediate-High or High Risk of
Recurrence Who Have Completed Definitive Locoregional
Treatment and Have No Evidence of Disease